Cellanyx Diagnostics Raises $1 Million to Advance the Biopsy of Living Tissue

What exactly is this “biopsy-on-a-chip?”

Beverly, MA — June 5, 2015 — Cellanyx Diagnostics, Inc., one of NSIV‘s Biotech startups, has raised $1 million in its effort to biopsy living tissue. Typically, cells are immersed in formaldehyde and then examined, a procedure that can often lead to the over-treatment or under-treatment of various diesases. Cellanyx’s new technology, “biopsy-on-a-chip,” is an extracellular matrix that analyzes multiple phenotypic, biochemical, and physical markers of individual living cells.

This technology allows for actionable assessments of individual cancer cells in biopsy samples, allowing scientists to assess various types of cancers more accurately. These “actionable assessments” are much more indicative of what is happening in a patient’s body than the sort of snapshot provided through analyzing cells immersed in formaldehyde.

To read more about this technology, visit pevc.dowjones.com. You can also visit Cellanyx Diagnostics’ website by clicking on the logo below.